Search
Capricor Therapeutics Inc
CAPRAdd to Watchlist
23.210USD
+0.140+0.61%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.34BMarket Cap
LossP/E TTM
More Details of Capricor Therapeutics Inc Company
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
Capricor Therapeutics Inc Info
Ticker SymbolCAPR
Company nameCapricor Therapeutics Inc
IPO dateJun 04, 2002
CEOMarban (Linda)
Number of employees160
Security typeOrdinary Share
Fiscal year-endJun 04
Address10865 Road to the Cure
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone13103583200
Websitehttps://capricor.com/
Ticker SymbolCAPR
IPO dateJun 04, 2002
CEOMarban (Linda)
Company Executives of Capricor Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
--
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
11.22K
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Karen G. Krasney, J.D.
Ms. Karen G. Krasney, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
Ms. Karimah Es Sabar
Ms. Karimah Es Sabar
Independent Director
Independent Director
--
--
Dr. Paul Auwaerter, M.D.
Dr. Paul Auwaerter, M.D.
Independent Director
Independent Director
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Kelliher
Mr. Michael Kelliher
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
--
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
11.22K
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Karen G. Krasney, J.D.
Ms. Karen G. Krasney, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Capricor Therapeutics Inc?
The top five shareholders of Capricor Therapeutics Inc are: Dr. Linda Marban, Ph.D.
How many institutions hold shares of Capricor Therapeutics Inc (CAPR)?
As of 2026Q1, 325 institutions hold shares of Capricor Therapeutics Inc, with a combined market value of approximately 31.81M, accounting for 54.99% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 10164129.00.